<!DOCTYPE html>
<html lang="cs">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>LAMY dokonƒçila strategickou akvizici inov√°tora v terapii rakoviny Exousia AI, Inc. | Marigold.cz Tech News</title>
    <meta name="description" content="Spoleƒçnost LAMY, kter√° se mƒõn√≠ na Exousia Bio, Inc. (OTCPINK: LMMY), ozn√°mila dokonƒçen√≠ akvizice 100 % pod√≠lu na Exousia AI, Inc. v transakci v√Ωhradnƒõ akciemi. ">
    <link rel="canonical" href="https://www.marigold.cz/tech-news/2025-12-02/lamy-completes-strategic-acquisition-of-cancer-the/">
    <style>
        * { margin: 0; padding: 0; box-sizing: border-box; }
        body { font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif; line-height: 1.6; color: #374151; background: #f3f4f6; }
        .container { max-width: 800px; margin: 0 auto; padding: 2rem; }
        .tech-news-article { background: white; border-radius: 12px; box-shadow: 0 4px 6px rgba(0,0,0,0.1); padding: 2rem; margin: 2rem 0; }
        .source-info { display: flex; align-items: center; gap: 0.75rem; margin-bottom: 1rem; flex-wrap: wrap; }
        .source-emoji { font-size: 1.5rem; }
        .source-name { font-weight: 600; color: #374151; }
        .importance-indicator { display: flex; gap: 2px; margin-left: auto; }
        .star { color: #fbbf24; font-size: 1.2rem; }
        .star.empty { color: #d1d5db; }
        .article-title { font-size: 2rem; font-weight: 700; line-height: 1.2; margin-bottom: 1rem; color: #111827; }
        .article-meta { display: flex; align-items: center; gap: 1rem; font-size: 0.875rem; color: #6b7280; margin-bottom: 1.5rem; }
        .category { padding: 0.25rem 0.75rem; border-radius: 1rem; font-weight: 500; font-size: 0.75rem; text-transform: uppercase; background: #e5e7eb; color: #374151; }
        .article-image { margin: 1.5rem 0; border-radius: 8px; overflow: hidden; }
        .article-image img { width: 100%; height: auto; display: block; }
        .article-content { font-size: 1.125rem; line-height: 1.7; margin-bottom: 2rem; }
        .article-content h2 { font-size: 1.5rem; margin: 1.5rem 0 1rem; color: #111827; }
        .article-content p { margin-bottom: 1rem; }
        .article-footer { border-top: 1px solid #e5e7eb; padding-top: 1.5rem; }
        .read-more-btn { display: inline-flex; align-items: center; gap: 0.5rem; padding: 0.75rem 1.5rem; background: #3b82f6; color: white; text-decoration: none; border-radius: 8px; font-weight: 500; }
        .read-more-btn:hover { background: #2563eb; }
        .original-title { margin-top: 1rem; color: #6b7280; font-size: 0.875rem; }
        .back-link { display: inline-block; margin-bottom: 1rem; color: #3b82f6; text-decoration: none; }
        .back-link:hover { text-decoration: underline; }
        .archive-notice { background: #fef3c7; border: 1px solid #f59e0b; border-radius: 8px; padding: 1rem; margin-bottom: 1rem; font-size: 0.875rem; color: #92400e; }
        @media (max-width: 640px) {
            .container { padding: 1rem; }
            .tech-news-article { padding: 1.5rem; margin: 1rem 0; }
            .article-title { font-size: 1.5rem; }
            .source-info { flex-direction: column; align-items: flex-start; }
            .importance-indicator { margin-left: 0; margin-top: 0.5rem; }
        }
    </style>
</head>
<body>
    <div class="container">
        <a href="/tech-news/" class="back-link">&larr; Zpƒõt na Tech News</a>

        <div class="archive-notice">
            Tento ƒçl√°nek je z archivu. Byl publikov√°n 02.12.2025.
        </div>

        <article class="tech-news-article">
            <header>
                <div class="source-info">
                    <span class="source-emoji">üì∞</span>
                    <span class="source-name">GlobeNewswire</span>
                    <div class="importance-indicator">
                        <span class="star">‚òÖ</span><span class="star">‚òÖ</span><span class="star">‚òÖ</span><span class="star empty">‚òÜ</span><span class="star empty">‚òÜ</span>
                    </div>
                </div>

                <h1 class="article-title">LAMY dokonƒçila strategickou akvizici inov√°tora v terapii rakoviny Exousia AI, Inc.</h1>

                <div class="article-meta">
                    <time datetime="2025-12-02T15:28:00+00:00">02.12.2025</time>
                    <span class="category">biotechnologie</span>
                </div>
            </header>

            
            <div class="article-image">
                <img src="https://ml.globenewswire.com/Resource/Download/7f557a35-9b11-49cc-a3ec-2379cd0e0b90" alt="LAMY dokonƒçila strategickou akvizici inov√°tora v terapii rakoviny Exousia AI, Inc." loading="lazy">
            </div>
        

            <div class="article-content">
                <h2>Souhrn</h2>
<p>Spoleƒçnost LAMY, nyn√≠ p≈ôech√°zej√≠c√≠ na Exousia Bio, Inc. (OTCPINK: LMMY), dokonƒçila akvizici 100 % akci√≠ Exousia AI, Inc. v transakci, p≈ôi n√≠≈æ vydala 62 223 000 omezen√Ωch akci√≠ sv√©ho z√°kladn√≠ho kapit√°lu. Tato akvizice sjednocuje vlastnictv√≠ pre-klinick√© onkologick√© platformy zalo≈æen√© na exozomech pro c√≠lenou dopravu l√©k≈Ø proti rakovinƒõ. Kl√≠ƒçov√Ωm prvkem je Orphan Drug Designation (ODD) od FDA pro terapii glioblastomu (GBM).</p>
<h2>Kl√≠ƒçov√© body</h2>
<ul>
<li>Vyd√°n√≠ 62 223 000 omezen√Ωch akci√≠ LAMY pro dokonƒçen√≠ akvizice.</li>
<li>Exkluzivn√≠ celosvƒõtov√© licence na technologie exozom≈Ø pro terapii rakoviny a jejich naƒç√≠t√°n√≠ l√©ky.</li>
<li>Orphan Drug Designation (ODD) od FDA pro pre-klinickou terapii glioblastomu, co≈æ p≈ôin√°≈°√≠ sedmiletou tr≈æn√≠ exkluzivitu.</li>
<li>Platforma umo≈æ≈àuje naƒç√≠t√°n√≠ exozom≈Ø z hum√°nn√≠ch i rostlinn√Ωch zdroj≈Ø pro ≈°k√°lovatelnou v√Ωrobu l√©k≈Ø.</li>
<li>Exousia Bio se profiluje jako americk√° biotechnologick√° firma zamƒõ≈ôen√° na exozomovou terapii rakoviny.</li>
</ul>
<h2>Podrobnosti</h2>
<p>Exousia Bio, Inc., d≈ô√≠ve LAMY, p≈Øsob√≠ jako americk√° biotechnologick√° spolecnost specializuj√≠c√≠ se na exozomy ‚Äì mal√© extracelul√°rn√≠ vezikuly, kter√© slou≈æ√≠ k p≈ôenosu biologick√Ωch sign√°l≈Ø mezi bu≈àkami. Tyto vezikuly umo≈æ≈àuj√≠ c√≠lenou dopravu l√©ƒçiv p≈ô√≠mo do rakovinn√Ωch bunƒõk, co≈æ sni≈æuje vedlej≈°√≠ √∫ƒçinky tradiƒçn√≠ch chemoterapi√≠. Akvizice Exousia AI, Inc. sjednotila vlastnictv√≠ pre-klinick√© platformy, kter√° zahrnuje dvƒõ exkluzivn√≠ celosvƒõtov√© licence na patentovan√© a patentovƒõ chr√°nƒõn√© technologie. Prvn√≠ licence pokr√Ωv√° pou≈æit√≠ exozom≈Ø v onkologii, druh√° se t√Ωk√° propriet√°rn√≠ metody naƒç√≠t√°n√≠ exozom≈Ø l√©ky, p≈ôiƒçem≈æ tato metoda funguje jak s hum√°nn√≠mi, tak rostlinn√Ωmi exozomy. Rostlinn√© exozomy p≈ôedstavuj√≠ v√Ωhodu v n√≠zk√Ωch v√Ωrobn√≠ch n√°kladech a snadn√© ≈°k√°lovatelnosti, co≈æ je kl√≠ƒçov√© pro p≈ôechod do klinick√Ωch f√°z√≠.</p>
<p>Nejv√Ωznamnƒõj≈°√≠m miln√≠kem je Orphan Drug Designation (ODD) udƒõlen√© FDA pro terapii glioblastomu multiforme (GBM), agresivn√≠ho n√°doru mozku s pr≈Ømƒõrnou p≈ôe≈æitelnost√≠ pacient≈Ø m√©nƒõ ne≈æ 15 mƒõs√≠c≈Ø. ODD, udƒõlen√© v pre-klinick√© f√°zi, je vz√°cn√© a signalizuje regulaƒçn√≠ uzn√°n√≠ potenci√°lu l√©ƒçby pro vz√°cn√© onemocnƒõn√≠ s nevy≈ôe≈°en√Ωmi zdravotn√≠mi pot≈ôebami. Tato status p≈ôin√°≈°√≠ sedmiletou tr≈æn√≠ exkluzivitu po schv√°len√≠, da≈àov√© √∫levy, poplatky za protokoly a urychlen√© schvalovac√≠ postupy. Transakce probƒõhla 2. prosince 2025 a byla ozn√°mena prost≈ôednictv√≠m GlobeNewswire. LAMY je notovan√° na OTC Pink trhu pod tickerem LMMY, co≈æ je m√©nƒõ regulovan√Ω segment ne≈æ hlavn√≠ burzy, co≈æ zvy≈°uje rizika pro investory kv≈Øli ni≈æ≈°√≠ likviditƒõ a transparentnosti. Exousia AI se zamƒõ≈ôovala na inovace v AI podporovan√©m designu l√©k≈Ø pro rakovinu, ale akvizice posiluje biologickou platformu sp√≠≈°e ne≈æ ƒçistƒõ v√Ωpoƒçetn√≠ slo≈æky.</p>
<h2>Proƒç je to d≈Øle≈æit√©</h2>
<p>Tato akvizice posouv√° Exousia Bio do pozice l√≠dra v exozomov√© terapii, kde trh s exozomov√Ωmi l√©ky roste d√≠ky slib≈Øm v personalizovan√© medic√≠nƒõ. ODD pro GBM otev√≠r√° dve≈ôe k dal≈°√≠m financ√≠m a partnerstv√≠m s velk√Ωmi farmaceutick√Ωmi firmami, kter√© hledaj√≠ inovace v onkologii. Pro pr≈Ømysl to znamen√° konkurenƒçn√≠ tlak na konvenƒçn√≠ terapie a potenci√°l pro rychlej≈°√≠ v√Ωvoj l√©k≈Ø d√≠ky ≈°k√°lovatelnosti rostlinn√Ωch exozom≈Ø. Nicm√©nƒõ pre-klinick√° f√°ze a OTC notace p≈ôipom√≠naj√≠ vysok√° rizika ‚Äì √∫spƒõ≈°nost p≈ôechodu do klinick√Ωch test≈Ø je pod 10 %. V ≈°ir≈°√≠m tech ekosyst√©mu to ukazuje na k≈ô√≠≈æen√≠ AI s biotech, kde algoritmy mohou optimalizovat design exozom≈Ø, ale zat√≠m chyb√≠ detaily o konkr√©tn√≠m AI nasazen√≠.</p>
<hr />
<p><a href="https://www.globenewswire.com/news-release/2025/12/02/3198198/0/en/LAMY-Completes-Strategic-Acquisition-of-Cancer-Therapy-Innovator-Exousia-AI-Inc.html">ƒå√≠st p≈Øvodn√≠ ƒçl√°nek</a></p>
<p><strong>Zdroj:</strong> üì∞ GlobeNewswire</p>
            </div>

            <footer class="article-footer">
                <a href="https://www.globenewswire.com/news-release/2025/12/02/3198198/0/en/LAMY-Completes-Strategic-Acquisition-of-Cancer-Therapy-Innovator-Exousia-AI-Inc.html" target="_blank" rel="noopener" class="read-more-btn">
                    ƒå√≠st p≈Øvodn√≠ ƒçl√°nek &rarr;
                </a>

                <div class="original-title"><small>P≈Øvodn√≠ n√°zev: LAMY Completes Strategic Acquisition of Cancer Therapy Innovator Exousia AI, Inc.</small></div>
            </footer>
        </article>

        <p style="text-align: center; color: #6b7280; font-size: 0.875rem; margin-top: 2rem;">
            &copy; 2025 <a href="https://www.marigold.cz" style="color: #3b82f6;">Marigold.cz</a>
        </p>
    </div>
</body>
</html>
